Xenon Pharmaceuticals (XENE) News Today $34.90 -1.55 (-4.25%) Closing price 04:00 PM EasternExtended Trading$33.22 -1.68 (-4.81%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Q1 Earnings Forecast for XENE Issued By William BlairMarch 21, 2025 | americanbankingnews.comWhat is William Blair's Forecast for XENE Q1 Earnings?Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at William Blair issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a research report issued on Monday, March 17th. William Blair analyst M. Minter forecasts that the biopharmaceutical company will post earningsMarch 20, 2025 | marketbeat.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical daily volume of 165 put options.March 20, 2025 | marketbeat.comXenon to Present at Stifel 2025 Virtual CNS ForumMarch 12, 2025 | financialpost.comXenon to Present at Stifel 2025 Virtual CNS ForumMarch 12, 2025 | globenewswire.comFMR LLC's Strategic Acquisition of Xenon Pharmaceuticals Inc. SharesMarch 7, 2025 | gurufocus.comCandriam S.C.A. Purchases 28,320 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Candriam S.C.A. boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 492,181 shares of theMarch 7, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are currently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average twelve-March 7, 2025 | marketbeat.comTraders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Investors acquired 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average daily volume of 165 put options.March 6, 2025 | marketbeat.comFY2028 EPS Estimate for Xenon Pharmaceuticals Cut by AnalystXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Wedbush dropped their FY2028 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Friday, February 28th. Wedbush analyst L. Chico now expectsMarch 3, 2025 | marketbeat.comQ1 Earnings Forecast for XENE Issued By HC WainwrightXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - HC Wainwright issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a report issued on Friday, February 28th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings per share of ($1.32) for theMarch 3, 2025 | marketbeat.comEquities Analysts Offer Predictions for XENE Q1 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Investment analysts at William Blair issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a report issued on Friday, February 28th. William Blair analyst M. Minter forecasts that the biopharmaceutical company will post earnings pMarch 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for XENE Q1 Earnings?Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a report released on Thursday, February 27th. Leerink Partnrs analyst M. Goodman forecasts that the biopharmaceMarch 3, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month Low - Time to Sell?Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month Low - Here's What HappenedMarch 1, 2025 | marketbeat.comXenon Pharmaceuticals' (XENE) "Outperform" Rating Reaffirmed at William BlairWilliam Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday.March 1, 2025 | marketbeat.comXenon Pharmaceuticals’ Earnings Call Highlights Progress and ChallengesMarch 1, 2025 | msn.comXenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPSXenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05.February 28, 2025 | marketbeat.comXenon Pharmaceuticals Inc.: Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business UpdateFebruary 28, 2025 | finanznachrichten.deXenon Pharmaceuticals price target lowered to $42 from $43 at WedbushFebruary 28, 2025 | markets.businessinsider.comXenon Pharmaceuticals price target raised to $58 from $56 at RBC CapitalFebruary 28, 2025 | markets.businessinsider.comXenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...February 28, 2025 | finance.yahoo.comXenon Pharmaceuticals reports Q4 EPS (84c), consensus (84c)February 28, 2025 | markets.businessinsider.comXenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comXenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business UpdateFebruary 27, 2025 | globenewswire.comHC Wainwright Has Bearish Estimate for XENE Q1 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Xenon Pharmaceuticals in a report released on Monday, February 24th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($1.00February 26, 2025 | marketbeat.comXenon to Present at the 45th Annual TD Cowen Healthcare ConferenceFebruary 25, 2025 | globenewswire.comHC Wainwright Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)HC Wainwright reissued a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday.February 24, 2025 | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Earnings on ThursdayXenon Pharmaceuticals (NASDAQ:XENE) will be releasing earnings before the market opens on Thursday, February 27.February 22, 2025 | marketbeat.comXenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025February 20, 2025 | financialpost.comXenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025February 20, 2025 | financialpost.comXenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025February 20, 2025 | globenewswire.comInvestors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors purchased 4,063 put options on the stock. This represents an increase of 2,362% compared to the typical volume of 165 put options.February 20, 2025 | marketbeat.comTimesSquare Capital Management LLC Has $33.28 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)TimesSquare Capital Management LLC lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 848,850 shares of the biopharmaceutical compFebruary 19, 2025 | marketbeat.comDeutsche Bank Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy RecommendationFebruary 12, 2025 | msn.comDeutsche Bank sets Xenon stock Buy rating, $67 price targetFebruary 11, 2025 | msn.comXenon Pharmaceuticals initiated with a Buy at Deutsche BankFebruary 11, 2025 | markets.businessinsider.comXenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated by Analysts at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a research report on Tuesday. They set a "buy" rating and a $67.00 target price for the company.February 11, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has been given a consensus rating of "Buy" by the eight brokerages that are covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the companFebruary 10, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by abrdn plcabrdn plc boosted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 14.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 283,899 shares of the biopharmaceutical company's stock after purchasing an additionaFebruary 8, 2025 | marketbeat.comXenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 4,063 put options on the stock. This is an increase of 2,362% compared to the average daily volume of 165 put options.February 6, 2025 | marketbeat.comJennison Associates LLC Purchases 224,892 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Jennison Associates LLC grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 39.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 801,553 shares of the biopharmaceutical company's stock after buFebruary 5, 2025 | marketbeat.comWe're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn RateFebruary 2, 2025 | finance.yahoo.comLeerink Partnrs Has Bearish Outlook for XENE FY2025 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceuJanuary 31, 2025 | marketbeat.comIan Mortimer Sells 16,315 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) StockJanuary 28, 2025 | insidertrades.comXenon Pharmaceuticals CEO sells shares worth $2.21 millionJanuary 27, 2025 | msn.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer Sells 16,315 SharesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at $1,267,731. This trade represents a 34.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.January 27, 2025 | marketbeat.comIan Mortimer Sells 22,468 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) StockXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 22,468 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.January 27, 2025 | marketbeat.comWedbush Lowers Earnings Estimates for Xenon PharmaceuticalsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical compaJanuary 27, 2025 | marketbeat.comFY2029 Earnings Estimate for XENE Issued By WedbushXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico forecasts that the biopharmaJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Comments on XENE FY2025 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Xenon Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the biopharmaceutical company will posJanuary 23, 2025 | marketbeat.com Remove Ads Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Media Mentions By Week XENE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼1.050.68▲Average Medical News Sentiment XENE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼84▲XENE Articles Average Week Remove Ads Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viatris News Ascendis Pharma A/S News Vaxcyte News Qiagen News Roivant Sciences News Sarepta Therapeutics News Revolution Medicines News BridgeBio Pharma News Lantheus News TG Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts